Cargando…

Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study

The prognosis of metastatic lung adenocarcinoma (MLUAD) varies greatly. At present, no studies have constructed a satisfactory prognostic model for MLUAD. We identified 44,878 patients with MLUAD. The patients were randomized into the training and validation cohorts. Cox regression models were perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bo, Chen, Jianhui, Zhang, Xiang, Feng, Nan, Xiang, Zhongtian, Wei, Yiping, Xie, Junping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750683/
https://www.ncbi.nlm.nih.gov/pubmed/36626448
http://dx.doi.org/10.1097/MD.0000000000032217
_version_ 1784850309937364992
author Wu, Bo
Chen, Jianhui
Zhang, Xiang
Feng, Nan
Xiang, Zhongtian
Wei, Yiping
Xie, Junping
Zhang, Wenxiong
author_facet Wu, Bo
Chen, Jianhui
Zhang, Xiang
Feng, Nan
Xiang, Zhongtian
Wei, Yiping
Xie, Junping
Zhang, Wenxiong
author_sort Wu, Bo
collection PubMed
description The prognosis of metastatic lung adenocarcinoma (MLUAD) varies greatly. At present, no studies have constructed a satisfactory prognostic model for MLUAD. We identified 44,878 patients with MLUAD. The patients were randomized into the training and validation cohorts. Cox regression models were performed to identify independent prognostic factors. Then, R software was employed to construct a new nomogram for predicting overall survival (OS) of patients with MLUAD. Accuracy was assessed by the concordance index (C-index), receiver operating characteristic curves and calibration plots. Finally, clinical practicability was examined via decision curve analysis. The OS time range for the included populations was 0 to 107 months, and the median OS was 7.00 months. Nineteen variables were significantly associated with the prognosis, and the top 5 prognostic factors were chemotherapy, grade, age, race and surgery. The nomogram has excellent predictive accuracy and clinical applicability compared to the TNM system (C-index: 0.723 vs 0.534). The C-index values were 0.723 (95% confidence interval: 0.719–0.726) and 0.723 (95% confidence interval: 0.718–0.729) in the training and validation cohorts, respectively. The area under the curve for 6-, 12-, and 18-month OS was 0.799, 0.764, and 0.750, respectively, in the training cohort and 0.799, 0.762, and 0.746, respectively, in the validation cohort. The calibration plots show good accuracy, and the decision curve analysis values indicate good clinical applicability and effectiveness. The nomogram model constructed with the above 19 prognostic factors is suitable for predicting the OS of MLUAD and has good predictive accuracy and clinical applicability.
format Online
Article
Text
id pubmed-9750683
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97506832022-12-28 Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study Wu, Bo Chen, Jianhui Zhang, Xiang Feng, Nan Xiang, Zhongtian Wei, Yiping Xie, Junping Zhang, Wenxiong Medicine (Baltimore) 5700 The prognosis of metastatic lung adenocarcinoma (MLUAD) varies greatly. At present, no studies have constructed a satisfactory prognostic model for MLUAD. We identified 44,878 patients with MLUAD. The patients were randomized into the training and validation cohorts. Cox regression models were performed to identify independent prognostic factors. Then, R software was employed to construct a new nomogram for predicting overall survival (OS) of patients with MLUAD. Accuracy was assessed by the concordance index (C-index), receiver operating characteristic curves and calibration plots. Finally, clinical practicability was examined via decision curve analysis. The OS time range for the included populations was 0 to 107 months, and the median OS was 7.00 months. Nineteen variables were significantly associated with the prognosis, and the top 5 prognostic factors were chemotherapy, grade, age, race and surgery. The nomogram has excellent predictive accuracy and clinical applicability compared to the TNM system (C-index: 0.723 vs 0.534). The C-index values were 0.723 (95% confidence interval: 0.719–0.726) and 0.723 (95% confidence interval: 0.718–0.729) in the training and validation cohorts, respectively. The area under the curve for 6-, 12-, and 18-month OS was 0.799, 0.764, and 0.750, respectively, in the training cohort and 0.799, 0.762, and 0.746, respectively, in the validation cohort. The calibration plots show good accuracy, and the decision curve analysis values indicate good clinical applicability and effectiveness. The nomogram model constructed with the above 19 prognostic factors is suitable for predicting the OS of MLUAD and has good predictive accuracy and clinical applicability. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750683/ /pubmed/36626448 http://dx.doi.org/10.1097/MD.0000000000032217 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5700
Wu, Bo
Chen, Jianhui
Zhang, Xiang
Feng, Nan
Xiang, Zhongtian
Wei, Yiping
Xie, Junping
Zhang, Wenxiong
Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
title Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
title_full Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
title_fullStr Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
title_full_unstemmed Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
title_short Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study
title_sort prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: a population-based study
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750683/
https://www.ncbi.nlm.nih.gov/pubmed/36626448
http://dx.doi.org/10.1097/MD.0000000000032217
work_keys_str_mv AT wubo prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT chenjianhui prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT zhangxiang prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT fengnan prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT xiangzhongtian prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT weiyiping prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT xiejunping prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy
AT zhangwenxiong prognosticfactorsandsurvivalpredictionforpatientswithmetastaticlungadenocarcinomaapopulationbasedstudy